Page 112 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
Zabaleta A, Puig N, Cedena Romero MT, Pérez JJ, Moreno C, Tamariz-Amador LE, Rodrí-
guez Otero P, González-Calle V, López Corral L, Rey-Búa B, Puertas Martínez B, Miras F,
Sánchez-Pina J, López N, Martínez-López J, Mateos MV, San-Miguel J, Paiva B.
• Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple
Myeloma (MM).
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023, San Diego,
CA, USA. Blood. 2023;142(Supplement 1):339. https://doi.org/10.1182/blood-2023-186916.
González C, Lasa M, Notarfranchi L, Agulló C, Buenache Cuenda N, Zherniakova A, Cas-
tro S, Pérez JJ, González-Calle V, Cedena Romero MT, Barrio S, Martín-Muñoz A, Burgos
L, Alignani D, Calasanz MJ, Rodríguez Otero P, Rosiñol L, De Arriba F, Ocio EM, Oriol Ro-
cafiguera A, Palomera L, González-Montes Y, Sureda Balari AM, Hernández García MT,
Clavero Sánchez ME, Ibañez García A, Gómez C, Orfao A, Mateos MV, Lahuerta Palacios
JJ, Bladé J, San-Miguel J, Martínez-López J, Puig N, Paiva B.
• Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple
Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM).
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023, San Diego,
CA, USA. Blood. 2023;142(Supplement 1):533. https://doi.org/10.1182/blood-2023-185737.
Pérez C, Larrayoz MJ, Vázquez I, Erdozain I, Puig N, Cedena MT, Maia C, Mañu A, Gordillo
N, Churruca O, Alignani D, Sarvide S, Oriol Rocafiguera A, Rosiñol L, Ríos R, González
Pérez MS, González-Rodríguez AP, De Arriba F, Moraleda JM, Martín Sánchez J, Palome-
ra L, Cabañas Perianes V, Calasanz MJ, Martínez-López J, Mateos MV, Bladé J, Lahuerta
Palacios JJ, San-Miguel J, Paiva B.
• Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By
Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple
Myeloma Treated in the GEM-CESAR Trial.
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023, San Diego,
CA, USA. Blood. 2023;142(Supplement 1):645. https://doi.org/10.1182/blood-2023-182964.
Puig N, Agulló C, Contreras T, Paiva B, Cedena Romero MT, Pérez JJ, Aires I, Martínez-
López J, Rodríguez Otero P, González-Calle V, González Pérez MS, Gutiérrez NC, Oriol
Rocafiguera A, Ríos R, Rosiñol L, Álvarez Rivas MA, Calasanz MJ, Bargay J, García-Sanz
R, González AP, Alegre A, Escalante F, Martínez R, De La Rubia J, Teruel AI, De Arriba F,
Palomera L, Castro S, Hernández García MT, López J, García Mateo A, Ocio EM, Bladé J,
Lahuerta Palacios JJ, San Miguel J, Mateos MV.
• Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs)
in Patients (Pts) with Multiple Myeloma (MM).
112